Skip Navigation


Europace Advance Access originally published online on May 7, 2007
Europace 2007 9(8):589-596; doi:10.1093/europace/eum072
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
9/8/589    most recent
eum072v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tziakas, D. N.
Right arrow Articles by Maltezos, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tziakas, D. N.
Right arrow Articles by Maltezos, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


BASIC SCIENCE

Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation

Dimitrios N. Tziakas1,*, Georgios K. Chalikias1, Nikolaos Papanas2, Dimitrios A. Stakos1, Sofia V. Chatzikyriakou1 and Efstratios Maltezos2

1 University Cardiology Department, Democritus University of Thrace, Voulgaroktonou 23, 68100 Alexandroupolis, Evros, Greece; 2 Second University Internal Medicine Department, Democritus University of Thrace, Alexandroupolis, Evros, Greece

Aims To investigate the hypothesis that circulating levels of collagen type I degradation or synthesis markers are associated with the presence and pattern of atrial fibrillation (AF).

Methods and results We assessed the serum concentrations of amino-terminal propeptide of procollagen type I (PINP) and of carboxy-terminal telopeptide of collagen type I (CITP), indexes of collagen type I synthesis and degradation, respectively, in 98 paroxysmal AF (PAF) patients (65 ± 14 years, 62 men), in 80 persistent AF (PsAF) patients (73 ± 8 years, 32 men), in 114 permanent AF (PmAF) patients (73 ± 10 years, 54 men), and in 180 patients in sinus rhythm (SR) (66 ± 13 years, 88 men) who represented a control group. Serum CITP levels were higher (P < 0.001) in AF patients [0.41 ng/mL, 95% confidence interval (CI) 0.38–0.44] when compared with SR patients (0.29 ng/mL, 95% CI 0.26–0.33) and were significantly different between the three AF pattern groups (P < 0.001). Patients with PAF (0.31 ng/mL, 95% CI 0.26–0.36) had lower CITP levels when compared with patients with PsAF (0.41 ng/mL, 95% CI 0.34–0.47) (P = 0.006), as well as with PmAF patients (0.49 ng/mL 95% CI, 0.43–0.56) (P < 0.001). Levels of CITP tended to be lower (P = 0.219) in PsAF patients when compared with sustained AF patients. No differences were found in PINP levels between AF and SR study groups (P = 0.637) as well as between the three AF pattern groups (P = 0.301).

Conclusion In the clinical setting, circulating levels of collagen type I degradation marker are associated with both type and duration of AF. Further studies are needed to evaluate the clinical use of serum concentrations of CITP as a potential diagnostic, prognostic, and therapeutic target in patients with AF.

Key Words: Atrial fibrillation, Collagen metabolism, Classification, Duration


* Corresponding author. Tel: +30 25510 35596; fax: +30 25510 35596. E-mail address: dtziakas{at}med.duth.gr

Manuscript submitted 18 September 2006. Accepted after revision 21 March 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
EuropaceHome page
M. Shimano, Y. Inden, Y. Tsuji, H. Kamiya, T. Uchikawa, R. Shibata, and T. Murohara
Circulating homocysteine levels in patients with radiofrequency catheter ablation for atrial fibrillation
Europace, August 1, 2008; 10(8): 961 - 966.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.